ABSTRACT BACKGROUND Long QT syndrome type 3 (LQT3) is a lethal disease caused by gain-of-function mutations in the
L ong QT syndrome type 3 (LQT3) is a rare variant of long QT syndrome (LQTS) caused by gain-offunction mutations in the gene SCN5A, coding for the sodium channel NaV1.5 (1) . Based on reports that the incidence of LQTS in neonates is 1:2,000 (2) and that LQT3 accounts for approximately 10% of LQTS patients (3), the incidence of LQT3 is estimated at 1:20,000.
LQT3 is characterized by a severe prognosis (3, 4) and an incomplete response to beta-blockers (5) , as compared to LQTS type 1, the most common LQTS variant. Since arrhythmic events in LQT3 occur predominantly at rest (6) , the value of beta-blocker therapy has been questioned (5, 7) , leaving the management of LQT3 patients uncertain.
This study is an extension of 2 pilot works we conducted in the late 1990s, when we demonstrated the ability of mexiletine to abbreviate the duration of ventricular repolarization in an animal model of LQT3 (8) and in LQT3 patients (9) . Those preliminary observations led to an off-label use of mexiletine in LQT3 patients, targeted to shorten the QT interval; this off-label use is now recommended in clinical practice guidelines (10) . Unfortunately, there is no evidence to support the hypothesis that, by shortening the QTc, this drug may also reduce the occurrence of life-threatening arrhythmias.
The objective of the study was to evaluate the ability of mexiletine to reduce the occurrence of arrhythmic events in LQT3 patients.
METHODS
We enrolled consecutive LQT3 patients referred to our center who accepted treatment with oral mexiletine.
For each individual, we collected demographic data, personal and family history, symptoms, arrhythmic events, and therapy at follow-up, which was then stored in a customized database. Additionally, we stored electrocardiogram (ECG) parameters for rhythm, heart rate, and duration of PR, QRS, and QT intervals. In addition, we obtained 12-lead ECGs (paper speed 25 mm/s and 10 mm/mV sensitivity) at stable heart rates close to 60 beats/min during daylight hours to limit the confounding effect of diurnal variability of QT interval (11) . The QT interval duration before and after therapy was measured in lead II, selecting beats preceded by similar RR intervals, as required when applying Bazett's formula. 
This illustration represents the predicted topology of the alpha subunit of the cardiac sodium channel (Nav1.5) and the position of the mutations identified in the 34 LQT3 patients who were treated with mexiletine. Blue circles ¼ individual mutations. This observation suggests that the therapeutic goal should not be related to the amount of QTc shortening, but rather to obtaining QTc values <500 ms.
Our study provided novel information on the tolerability of long-term mexiletine in young LQT3 patients including infants. Importantly, none of the patients who were asymptomatic before mexiletine experienced an arrhythmic event on the agent.
It is becoming increasingly difficult to find mex- 
CONCLUSIONS
We reported here the first observation that a medication, other than beta-blockers, is able to reduce the occurrence of arrhythmic events in LQT3 patients, corroborating the hypothesis that mexiletine may improve survival in these patients. Overall, our data supported the view that precision medicine can be applied to the management of LQTS patients, guiding not only risk stratification, but also the identification of therapies able to modify the molecular mechanism of the disease.
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